12.01

1.44% 0.17

Avalo Therapeutics Inc (AVTX)

Panoramica Notizia Cronologia dei prezzi Catena di opzioni Financials Forum Previsione Frazionamento azionario

Precedente Chiudi:

$11.84

Aprire:

$11.93

Volume 24 ore:

801.60K

Relative Volume:

0.86

Capitalizzazione di mercato:

$644.10M

Reddito:

$59,000

Utile/perdita netta:

$-84.74M

Rapporto P/E:

-2.0628

EPS:

-5.8222

Flusso di cassa netto:

$-59.69M

1 W Prestazione:

-10.57%

1M Prestazione:

-25.26%

6M Prestazione:

-10.04%

1 anno Prestazione:

-13.60%

Intervallo 1D:

$11.70

$12.35

Intervallo di 1 settimana:

$11.58

$13.82

Portata 52W:

$11.58

$24.27

Avalo Therapeutics Inc Stock (AVTX) Company Profile

Nome

Avalo Therapeutics Inc

Settore

Healthcare (1051)

Industria

Biotechnology (593)

Telefono

410-522-8707

Indirizzo

1500 LIBERTY RIDGE DRIVE, WAYNE

Dipendente

Cinguettio

Prossima data di guadagno

2026-11-05

Ultimi documenti SEC

AVTX's Discussions on Twitter

Compare AVTX vs VRTX, MRNA, REGN, ARGX, ONC

Azioni	Prezzo	Cap. di mercato	Reddito	Reddito netto	Flusso di cassa	EPS
AVTX Avalo Therapeutics Inc	12.01	644.10M	59,000	-84.74M	-59.69M	-5.8222
VRTX Vertex Pharmaceuticals Inc	508.74	128.95B	12.34B	4.34B	3.71B	16.87
MRNA Moderna Inc	236.50	94.42B	2.23B	-3.19B	-1.60B	-8.1462
REGN Regeneron Pharmaceuticals Inc	796.35	81.99B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	846.50	53.23B	4.16B	1.29B	734.26M	19.58
ONC Beone Medicines Ltd Adr	374.30	42.34B	5.76B	514.49M	1.10B	4.4813

Avalo Therapeutics Inc Stock (AVTX) Upgrades & Downgrades

Data	Azione	Analista	Modifica della valutazione
2026-07-06	Iniziato	Leerink Partners	Outperform
2026-06-12	Iniziato	BofA Securities	Buy
2026-04-09	Iniziato	Wolfe Research	Outperform
2026-04-06	Iniziato	Citizens	Mkt Outperform
2026-02-02	Iniziato	Guggenheim	Buy
2025-12-18	Iniziato	Mizuho	Outperform
2025-09-17	Reiterato	H.C. Wainwright	Buy
2025-09-05	Iniziato	TD Cowen	Buy
2025-08-15	Iniziato	Cantor Fitzgerald	Overweight
2025-06-02	Ripresa	H.C. Wainwright	Buy
2025-03-25	Iniziato	Jefferies	Buy
2025-03-25	Iniziato	Stifel	Buy
2025-02-28	Iniziato	Piper Sandler	Overweight
2025-02-21	Iniziato	Wedbush	Outperform
2024-12-19	Iniziato	BTIG Research	Buy
2024-10-24	Iniziato	H.C. Wainwright	Neutral
2024-04-16	Aggiornamento	Oppenheimer	Perform → Outperform
2021-09-24	Iniziato	RBC Capital Mkts	Outperform

Mostra tutto

Avalo Therapeutics Inc Borsa (AVTX) Ultime notizie

Oct 02, 2026

In lieu of Board fees, Avalo Therapeutics (AVTX) grants Rita Jain 1,322 fully vested stock options. - Stock Titan

Oct 02, 2026

1,352 fully vested options replace Board fees for Avalo Therapeutics (AVTX) director Kevin Robert Lind. - Stock Titan

Oct 02, 2026

In lieu of board fees, Avalo Therapeutics (AVTX) grants Ron M. Philip 1,109 stock options. - Stock Titan

Oct 02, 2026

Sep 29, 2026

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - The Manila Times

Sep 29, 2026

Three new hires receive options to buy Avalo shares for $15.47 each - Stock Titan

Sep 29, 2026

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Sep 29, 2026

Sep 18, 2026

Avalo Therapeutics CFO Christopher Sullivan Executes Option Exercise and Sells 12,394 Shares via 10b5-1 Plan - Kalkine Media

Sep 18, 2026

Avalo Therapeutics (AVTX) CFO sells 12K shares after option exercise - Stock Titan

Sep 18, 2026

Sep 13, 2026

AVTX 8-K FilingsAvalo Therapeutics, Inc. SEC 8-K - Stock Titan

Sep 13, 2026

Sep 11, 2026

Avalo Therapeutics (AVTX) CFO sells shares at $17.62 average, keeps 105K options - Stock Titan

Sep 11, 2026

Sep 10, 2026

Avalo Therapeutics at Cantor conference: building around il-1 beta By Investing.com - Investing.com Canada

Sep 10, 2026

Sep 06, 2026

(AVTX) Price Dynamics and Execution-Aware Positioning - Stock Traders Daily

Sep 06, 2026

Sep 04, 2026

Avalo Therapeutics Announces Inducement Grants to New Employees Under Nasdaq Listing Rule 5635(c)(4) - Moomoo

Sep 04, 2026